Plasminogen activator system in human breast cancer

✍ Scribed by K. Sumiyoshi; K. Serizawa; T. Urano; Y. Takada; A. Takada; S. Baba

• Book ID: 102277074
• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 438 KB
• Volume: 50
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910500303

✦ Synopsis

We measured antigen levels of 2 kinds of plasminogen activator, tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (UK), as well as those of their primary inhibitors, type-I plasminogen activator inhibitor (PAL I) and type-2 plasminogen activator inhibitor (PAI-2), in tissue extracts from benign and malignant breast tumors.

Tumor tissue samples from 40 fibroadenomas and 40 breast cancers were examined. t-PA antigen levels were the same in the 2 groups. Malignant tumors contained higher levels of UK antigen than did benign tumors. In the case of breast cancer, UK antigen levels of tumors with axillary lymph-node involvement were significantly higher than those of tumors without lymphnode involvement. PAI-I and PAI-2 antigen levels of breastcancer tissue samples were higher than those of fibroadenoma samples. PAL I antigen levels of carcinomas with lymph-node involvement were also significantly higher than those of carcinomas without node involvement. PAL2 antigen levels, on the contrary, were higher in carcinomas without node involvement. UK, PAI-I and PAL2 antigen levels are potentially excellent independent factors for prediction of the metastatic potential of breast cancers.